$ITOS
iTeos Therapeutics, Inc.

2020 Q3 Form 10-Q Financial Statement

#000156459020053269 Filed on November 12, 2020

View on sec.gov

Income Statement

Concept 2020 Q3 2019 Q3 2019 Q2
Revenue $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $4.800M
YoY Change
% of Gross Profit
Research & Development $8.726M $3.902M
YoY Change
% of Gross Profit
Depreciation & Amortization $140.0K
YoY Change
% of Gross Profit
Operating Expenses $13.53M $5.995M
YoY Change
Operating Profit -$13.53M -$5.995M
YoY Change
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net $265.0K -$47.00K
YoY Change
Pretax Income -$10.69M -$5.697M
YoY Change
Income Tax -$8.000K $29.00K $58.00K
% Of Pretax Income
Net Earnings -$10.68M -$6.921M -$5.755M
YoY Change 54.31%
Net Earnings / Revenue
Basic Earnings Per Share -$0.48
Diluted Earnings Per Share -$0.48
COMMON SHARES
Basic Shares Outstanding 24.35M
Diluted Shares Outstanding 24.35M

Balance Sheet

Concept 2020 Q3 2019 Q3 2019 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $340.0M
YoY Change
Cash & Equivalents $340.1M $26.34M $33.26M
Short-Term Investments
Other Short-Term Assets $3.300M
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $345.7M
YoY Change
LONG-TERM ASSETS
Property, Plant & Equipment $1.300M
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $400.0K
YoY Change
Total Long-Term Assets $5.200M
YoY Change
TOTAL ASSETS
Total Short-Term Assets $345.7M
Total Long-Term Assets $5.200M
Total Assets $350.9M
YoY Change
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.400M
YoY Change
Accrued Expenses $6.054M
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $10.30M
YoY Change
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities $5.000M
YoY Change
Total Long-Term Liabilities $5.000M
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $10.30M
Total Long-Term Liabilities $5.000M
Total Liabilities $15.30M
YoY Change
SHAREHOLDERS EQUITY
Retained Earnings -$58.99M
YoY Change
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $335.6M -$30.45M -$21.68M
YoY Change
Total Liabilities & Shareholders Equity $350.9M
YoY Change

Cashflow Statement

Concept 2020 Q3 2019 Q3 2019 Q2
OPERATING ACTIVITIES
Net Income -$10.68M -$6.921M -$5.755M
YoY Change 54.31%
Depreciation, Depletion And Amortization $140.0K
YoY Change
Cash From Operating Activities -$10.23M
YoY Change
INVESTING ACTIVITIES
Capital Expenditures -$100.0K
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$100.0K
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 212.9M
YoY Change
NET CHANGE
Cash From Operating Activities -10.23M
Cash From Investing Activities -100.0K
Cash From Financing Activities 212.9M
Net Change In Cash 202.6M
YoY Change
FREE CASH FLOW
Cash From Operating Activities -$10.23M
Capital Expenditures -$100.0K
Free Cash Flow -$10.13M
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2019Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
51757000
CY2020Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
97000
CY2020Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8726000
CY2020Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-58994000
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
335626000
CY2020Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
350944000
CY2020Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2020Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
35044758
CY2020Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
35044758
CY2020Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2020Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2020Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q3 us-gaap Operating Expenses
OperatingExpenses
13525000
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-13525000
CY2020Q3 itos Grant Income
GrantIncome
2299000
CY2019Q3 itos Fair Value Adjustment For Preferred Stock Tranche Rights And Anti Dilution Warrant Liabilities
FairValueAdjustmentForPreferredStockTrancheRightsAndAntiDilutionWarrantLiabilities
-230000
itos Fair Value Adjustment For Preferred Stock Tranche Rights And Anti Dilution Warrant Liabilities
FairValueAdjustmentForPreferredStockTrancheRightsAndAntiDilutionWarrantLiabilities
1265000
itos Fair Value Adjustment For Preferred Stock Tranche Rights And Anti Dilution Warrant Liabilities
FairValueAdjustmentForPreferredStockTrancheRightsAndAntiDilutionWarrantLiabilities
66000
itos Research And Development Tax Credits
ResearchAndDevelopmentTaxCredits
539000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-77000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-16991000
CY2019Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
29000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-58000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
87000
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-6921000
us-gaap Net Income Loss
NetIncomeLoss
-23129000
us-gaap Net Income Loss
NetIncomeLoss
-17078000
CY2020Q3 us-gaap Dividends Preferred Stock
DividendsPreferredStock
36000
CY2019Q3 us-gaap Dividends Preferred Stock
DividendsPreferredStock
107000
us-gaap Dividends Preferred Stock
DividendsPreferredStock
249000
us-gaap Dividends Preferred Stock
DividendsPreferredStock
320000
CY2020Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-11647000
CY2019Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-7991000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-28498000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-19973000
CY2020Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.48
CY2019Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-43.03
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-3.40
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-107.55
CY2020Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
24349222
CY2019Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
185716
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
8376860
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
185716
CY2019Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-1090000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
321000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-828000
CY2019Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-8011000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-22808000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-17906000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
-10678000
CY2019Q1 itos Temporary Equity Accretion To Redemption Value Increase Decrease
TemporaryEquityAccretionToRedemptionValueIncreaseDecrease
697000
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
205000
CY2019Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-267000
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-4402000
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
-15839000
CY2019Q2 itos Temporary Equity Accretion To Redemption Value Increase Decrease
TemporaryEquityAccretionToRedemptionValueIncreaseDecrease
915000
CY2019Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
102000
CY2019Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
203000
CY2019Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
529000
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-5755000
CY2019Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
201000
CY2019Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-1090000
CY2019Q3 us-gaap Stockholders Equity
StockholdersEquity
-30448000
CY2020Q1 itos Settlement Of Preferred Stock Tranche Right
SettlementOfPreferredStockTrancheRight
4135000
CY2020Q1 itos Temporary Equity Accretion To Redemption Value Increase Decrease
TemporaryEquityAccretionToRedemptionValueIncreaseDecrease
1195000
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
186000
CY2020Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-317000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-5247000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
-38526000
CY2020Q2 itos Temporary Equity Accretion To Redemption Value Increase Decrease
TemporaryEquityAccretionToRedemptionValueIncreaseDecrease
2994000
CY2020Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
205000
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
350000
CY2020Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
245000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-7202000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
-47922000
CY2020Q3 itos Temporary Equity Accretion To Redemption Value Increase Decrease
TemporaryEquityAccretionToRedemptionValueIncreaseDecrease
931000
CY2020Q3 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
181903000
CY2020Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
210699000
CY2020Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
450000
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1714000
CY2020Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
393000
CY2020Q3 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
19000000
us-gaap Profit Loss
ProfitLoss
-23129000
us-gaap Profit Loss
ProfitLoss
-17078000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
392000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
465000
us-gaap Share Based Compensation
ShareBasedCompensation
2250000
us-gaap Share Based Compensation
ShareBasedCompensation
609000
itos Deferred Rent Adjustments
DeferredRentAdjustments
11000
itos Deferred Rent Adjustments
DeferredRentAdjustments
8000
itos Increase Decrease In Grants Receivable
IncreaseDecreaseInGrantsReceivable
3007000
itos Increase Decrease In Grants Receivable
IncreaseDecreaseInGrantsReceivable
-2159000
itos Increase Decrease In Research And Development Tax Credit Receivable
IncreaseDecreaseInResearchAndDevelopmentTaxCreditReceivable
505000
itos Increase Decrease In Research And Development Tax Credit Receivable
IncreaseDecreaseInResearchAndDevelopmentTaxCreditReceivable
467000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2346000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-7000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
901000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-408000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1579000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-882000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1635000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-585000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
1268000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-19712000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-16202000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
222000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
737000
us-gaap Payments To Acquire Other Productive Assets
PaymentsToAcquireOtherProductiveAssets
21000
us-gaap Payments To Acquire Other Productive Assets
PaymentsToAcquireOtherProductiveAssets
145000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-243000
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
213660000
itos Payments For Initial Public Offering Costs
PaymentsForInitialPublicOfferingCosts
2691000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
655000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
102000
us-gaap Proceeds From Repayments Of Related Party Debt
ProceedsFromRepaymentsOfRelatedPartyDebt
2856000
us-gaap Proceeds From Repayments Of Related Party Debt
ProceedsFromRepaymentsOfRelatedPartyDebt
65000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
339506000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
22539000
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
566000
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-1165000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
320117000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
4290000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
19990000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
22054000
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
340107000
CY2019Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
26344000
us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
181903000
us-gaap Preferred Stock Accretion Of Redemption Discount
PreferredStockAccretionOfRedemptionDiscount
5120000
us-gaap Preferred Stock Accretion Of Redemption Discount
PreferredStockAccretionOfRedemptionDiscount
2575000
itos Settlement Of Preferred Stock Tranche Right
SettlementOfPreferredStockTrancheRight
4135000
itos Initial Public Offering Costs Included In Accounts Payable
InitialPublicOfferingCostsIncludedInAccountsPayable
270000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
147000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
20000
itos Proceeds Received From Grants
ProceedsReceivedFromGrants
1416000
CY2020Q3 itos Proceeds Received From Grants
ProceedsReceivedFromGrants
659000
CY2020Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2440000
CY2019Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2081000
itos Proceeds Received From Grants
ProceedsReceivedFromGrants
10488000
CY2019Q3 itos Proceeds Received From Grants
ProceedsReceivedFromGrants
516000
CY2019Q3 us-gaap Grants Receivable Current
GrantsReceivableCurrent
5196000
us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Use of estimates</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of the Company&#8217;s consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, and expenses, as well as the related disclosures of contingent assets and liabilities. Estimates are used to determine the fair value of the preferred stock tranche rights liability and anti-dilution warrants liability, the fair value of profit certificates, common stock and stock-based awards and other issuances, accruals for research and development costs, useful lives of long-lived assets, probability of repayment for grants repayable, and uncertain tax positions. Actual results could differ materially from the Company&#8217;s estimates.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The full extent to which the COVID-19 pandemic will directly or indirectly impact the Company&#8217;s business, results of operations and financial condition, including expenses, research and development costs and employee-related amounts, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain or treat COVID-19, as well as the economic impact on local, regional, national and international markets. The Company has considered the impact of COVID-19 on estimates within its financial statements and there may be changes to those estimates in future periods. As of the date of issuance of these unaudited condensed consolidated financial statements, the Company has not experienced material business disruptions or incurred impairment losses in the carrying value of its assets as a result of the pandemic and is not aware of any specific related event or circumstance that would require it to update its estimates.</p>
CY2020Q3 us-gaap Deferred Income Noncurrent
DeferredIncomeNoncurrent
4488000
CY2019Q3 us-gaap Deferred Income Noncurrent
DeferredIncomeNoncurrent
1397000
CY2020Q2 us-gaap Depreciation And Amortization
DepreciationAndAmortization
100000
CY2019Q2 us-gaap Depreciation And Amortization
DepreciationAndAmortization
200000
CY2020Q3 itos Accrued Clinical Trial Costs Current
AccruedClinicalTrialCostsCurrent
3426000
CY2019Q4 itos Accrued Clinical Trial Costs Current
AccruedClinicalTrialCostsCurrent
2683000
CY2020Q3 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
319680000
CY2020Q3 us-gaap Financial Instruments Owned At Fair Value
FinancialInstrumentsOwnedAtFairValue
319680000
CY2019Q4 us-gaap Financial Instruments Owned At Fair Value
FinancialInstrumentsOwnedAtFairValue
5400000
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
0
CY2020Q1 itos Preferred Stock Tranche Rights Liability
PreferredStockTrancheRightsLiability
0
CY2019Q4 itos Anti Dilution Warrants
AntiDilutionWarrants
0
CY2020Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
3727000
CY2019Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
3417000
CY2020Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
25000
CY2019Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
30000
CY2020Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
57000
CY2019Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
140000
CY2020Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6054000
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4262000
us-gaap Research And Development Arrangement With Federal Government Costs Incurred Net
ResearchAndDevelopmentArrangementWithFederalGovernmentCostsIncurredNet
3500000
CY2020Q3 itos Accrued Personnel Costs Current
AccruedPersonnelCostsCurrent
2546000
CY2019Q4 itos Accrued Personnel Costs Current
AccruedPersonnelCostsCurrent
1409000
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
54000
CY2020Q3 us-gaap Common Stock Voting Rights
CommonStockVotingRights
Each share of common stock entitles the holders to one vote on all matters submitted to a vote of the Company’s stockholders.
CY2020Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1714000
CY2019Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
201000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2250000
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1387003
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
3278998
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
59076
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
236459
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4370466
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
747745
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.62
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
9.48
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
5.20
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
2.77
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.36
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
5.11
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P4Y9M18D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y3M18D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
71284000
CY2020Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
14629000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
7.00
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.49
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0036
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0251
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0036
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0135
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.92
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.93
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.90
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.92
CY2020Q3 itos Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Common Stock
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsCommonStock
19.00
itos Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Common Stock
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsCommonStock
2.38
CY2020Q3 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P4Y
us-gaap Lease And Rental Expense
LeaseAndRentalExpense
400000
us-gaap Lease And Rental Expense
LeaseAndRentalExpense
400000
CY2020Q3 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
200000
CY2019Q3 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
200000
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
150000
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
593000
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
173000
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
22000
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
992000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4370466
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9920677

Files In Submission

Name View Source Status
0001564590-20-053269-index-headers.html Edgar Link pending
0001564590-20-053269-index.html Edgar Link pending
0001564590-20-053269.txt Edgar Link pending
0001564590-20-053269-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
itos-10q_20200930.htm Edgar Link pending
itos-20200930.xml Edgar Link completed
itos-20200930.xsd Edgar Link pending
itos-20200930_cal.xml Edgar Link unprocessable
itos-20200930_def.xml Edgar Link unprocessable
itos-20200930_lab.xml Edgar Link unprocessable
itos-20200930_pre.xml Edgar Link unprocessable
itos-ex311_6.htm Edgar Link pending
itos-ex312_7.htm Edgar Link pending
itos-ex321_8.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending